Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    23246368 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612
Condition: Meningococcal Serogroups A, C, W-135 and/or Y Disease
Interventions: Biological: Meningococcal vaccine 134612;   Biological: Mencevax™ ACWY

Indicates status has not been verified in more than two years